Immunotherapy of Breast Cancer Using Novel Her2/neu-Based Vaccines
Abstract
Breast cancer is the most common malignancy in women. In U.S., 180,000 new cases are diagnosed and 45,000 deaths occur each year, Current therapy for this disease is aggressive and frequently mulitating. We have been developing a Listeria monocytogenes based Her2/neu vaccine for breast cancer. L. monocytogenes has been successfully used as a vaccine vector and tested in several disease models. To improve our immunotherapeutic approach to breast cancer, we are currently investigating the NY-ESO-l antigen, which is expressed in a large proportion of breast cancers. NY-ESO-l is the most immunogenic member of the Cancer-Testis antigen family. It is now widely accepted that tumors can escape immunotherapies targeting a single antigen by losing expression of that antigen. In this case, association of Her2/neu and NY-ESO-l could provide a more efficient vaccine against breast cancer. In this study, we constructed several NY-ESO-l recombinant-Listeria - monocytogenes. We found that the C-term region of NY-ESO-1, which contains the important HLA-A2/l57-165 epitope, is poorly secreted by Listeria. We are also generating a NT-2 (her2/neu positive) and 4T1-based breast cancer models in the mouse to test our NY-ESO-l and Her2/neu vaccines. These recombinant L. monocytogenes-based vaccines are a potential therapeutic strategy for breast cancer treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2004
- Accession Number
- ADA425723
Entities
People
- Paulo Maciag
Organizations
- University of Pennsylvania